NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1341.60 4.30 (0.32%)

31.53% Gain from 52W Low

851.4K NSE+BSE Volume

NSE 25 Jun, 2025 3:31 PM (IST)

111,967.5

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Dividend

Dr. Reddy's Laboratories Ltd. has an upcoming dividend of ₹8.00 per share due on 10 Jul 2025 See details

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

29 Jul 2020

1341.60

0.32%

Q1FY21 Result Update - EBITDAM beat due to better gross margin - HOLD

Hold: Dr. Reddy's Laboratories Ltd.

Prabhudas Lilladhar

We downgrade DRRD to HOLD (earlier Accumulate) due to limited upside potential at current valuation. We retain our earnings estimates and TP of Rs4,326 (PE 24x FY22E). DRRD continues to be one of the best companies in large cap pharma space structurally, though there is limited headroom for further upgrade in earnings estimate and PE expansion. However re-rating in...

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

29 May 2020

1341.60

0.32%

DR. REDDY'S LABORATARIES

Buy: Dr. Reddy's Laboratories Ltd.

Recommendation Target

Geojit BNP Paribas

Strong pipeline and new product launches are the key positives. Additionally, smooth operation ahead of VAI from US FDA for the company's facilities should support topline growth over the medium term. Hence, we upgrade our rating to BUY on the stock with a revised target price of Rs. 4,344 based on 23x FY22E adj. EPS....

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

26 May 2020, 12:00AM

1341.60

0.32%

Dr. Reddy`s Laboratories Limited

Results Update: Dr. Reddy's Laboratories Ltd.

SMC online

Dr Reddy's Labs spurts after Q4 PAT jumps 76% to 764 cr, above estimates On a consolidated basis, the drug major recorded net profit of Rs 781.10crore in Q4 March 2020 compared with net profit of Rs 455.40 crore in Q4 March 2019. Consolidated revenues rose...

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

22 May 2020

1341.60

0.32%

Dr. Reddy's Result Review- March 2020

Hold: Dr. Reddy's Laboratories Ltd.

Target

Hem Securities

Dr Reddy's Laboratories has been catering to the needs of the pharmaceutical sector for over two decades. Active Pharmaceutical Ingredients (API) are their core strength, having a wide range of portfolio. The company also manufactures generic medicines with business spread across India, Russia, US and Germany as well as Proprietary Products which inlcudes NCE research, biologics business and differentiated formulations conducted in the US. Under this the...

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

21 May 2020

1341.60

0.32%

Q4FY20 Result Update - Beats estimate on all counts due to US-Gx, EU - Accumulate

Accumulate: Dr. Reddy's Laboratories Ltd.

Target

Prabhudas Lilladhar

We continue to believe that DRRD is one of the best play in large-cap pharma space a) due to its control on overhead expenses, b) focus on domestic business, c) injectable pipeline for US and EU, d) net cash on books and e) resolution for all major FDA issues. Over FY21-22E, DRRD will likely see change is business mix with high margin domestic formulation (17% of...

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

21 May 2020

1341.60

0.32%

Results Update: Dr. Reddy's Laboratories Ltd

Hold: Dr. Reddy's Laboratories Ltd.

Target

Karvy

Strong Results on Inventory Stocking:Revenues for the quarter increased by 10% to Rs 44.3 bn due to strong performance in US and Europe.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

21 May 2020

1341.60

0.32%

Dr Reddy's Laboratories

Buy: Dr. Reddy's Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Revenues grew 10.4% YoY to | 4448.9 crore, mainly due to strong growth in the US and Europe. Domestic revenues grew 5.1% YoY to | 683.9 crore. US revenues grew 20.8% YoY to | 1807.2 crore. Despite a dent in GM, EBITDA margins expanded 101 bps to 21.3% due to lower employee and other expenses. EBITDA grew 15.9% YoY to | 949.2 crore. Adjusted net profit grew 71.5% YoY to | 781.1 crore. Delta vis--vis EBITDA was mainly...

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

20 May 2020

1341.60

0.32%

Superior execution in US/EU drives earnings

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

We raise our EPS estimate by 2%/5% for FY21/FY22 to factor a healthy ANDA pipeline for the US market and a growing reach in the Europe markets. We further raise the PE multiple to 22x (from 21x earlier) to factor the resolution of compliance issues at all sites of DRRD. Accordingly, we revise our price target to INR3,775 (from INR3,490 earlier). led by all businesses, except Pharma Services and Active Ingredients (PSAI). The US business (40% of sales) was up 21% YoY to INR18.1b (USD240m). The Europe business (8% of sales) increased 80% YoY. The India business (15% of sales) was up 5% YoY to INR6.8b. Emerging Markets (18% of sales) expanded 15% YoY to INR8b, led by strong growth in the CIS segment. The PSAI segment (16% of sales) grew at a moderate rate of 6% YoY to INR7.2b.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

20 May 2020

1341.60

0.32%

Dr Reddy's Labs (ADD): EBITDA miss; risk-reward fair TP raised to Rs 4,210

Dr. Reddy's Laboratories Ltd.

BOB Capital Markets Ltd.

Q4 EBITDA of Rs 9.4bn (8% QoQ) was a miss despite a strong beat in the US and Europe, cost control, and net forex benefits.

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

08 May 2020

1341.60

0.32%

Dr Reddy's Labs (ADD): EIR for Srikakulam (CTO-VI) API unit

Sell: Dr. Reddy's Laboratories Ltd.

BOB Capital Markets Ltd.

Dr Reddy's Labs (DRRD) announced that it has received an EIR (establishment inspection report) from the USFDA for its Srikakulam (CTO-VI) API facility.

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Is Dr. Reddy's Laboratories Ltd. worth buying?

511 Votes:

Buy 78.28%

Sell 12.13%

Hold 9.59%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf